Faraday Pharmaceuticals Analysis: $120M Raised
What is Faraday Pharmaceuticals?
Faraday Pharmaceuticals develops FDY-5301, a Phase 3 clinical trial program targeting ischemia-reperfusion injury during ST-elevation myocardial infarction. The drug uses sodium iodide to neutralize hydrogen peroxide, reducing cardiac and skeletal muscle damage. It is designed to complement percutaneous coronary intervention in acute cardiac care.
Location
Seattle, United States
Employees
11-50
Founded
2014
Funding Status
Series C
Product Features & Capabilities
- FDY-5301 (Phase 3 clinical trial)
- Sodium iodide therapy to neutralize hydrogen peroxide
- Preclinical models showing reduced tissue damage and infarct size
Use Cases
Administer FDY-5301 during PCI for STEMI to reduce cardiac damage; Use in acute cardiac care to minimize infarct size; Apply sodium iodide therapy to reduce inflammation and tissue injury during reperfusion
Other Considerations
Phase 3 clinical trial (Iocyte AMI-3) ongoing; Completed Phase 2 trial (Iocyte AMI) with promising results; Developed by Dr. Mark Roth of Fred Hutchinson Cancer Center; Investigating sodium iodide as novel approach to ischemia-reperfusion injury
See something that needs updating? Suggest edits to this profile.